Archive - October 2023
FDA Accepts Defender Pharmaceuticals’ New Drug Application for Intranasal Scopolamine Gel
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
Alpha Cognition Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
Basilea Announces FDA Acceptance of New Drug Application for Antibiotic Ceftobiprole
Medical Device Sales – Modesto, CA
Clinical Specialist
Biopsy Sales Specialist – Miami, FL
Territory Sales Representative